Russia plans to speed the replacement of imported drugs by domestic generics

15 March 2024

Russia plans to speed the replacement of imported drugs by domestic generics with the aim of raising state security in the field of pharmaceutics and drugs assistance, reports The Pharma Letter’s local correspondent.

This will be part of the existing state strategy for the “Development of Pharmaceutical Industry in Russia until 2030,” the main legislative act, which regulates the development of pharmaceutical industry in Russia within the next six years.

That has been recently confirmed by the Russian Health Minister Mikhail Murashko. According to him, the Russian pharmaceutical industry has the needed capabilities and intellectual potential to replace foreign drugs and medical equipment already in the middle term, while the work in this direction is ongoing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Generics